Favipiravir (T-705) inhibits in vitro norovirus replication.
Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment/prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.
Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.° 228, 4050-313 Porto, Portugal.
J
J
Rocha-Pereira
D
D
Jochmans
K
K
Dallmeier
P
P
Leyssen
M S J
MS
Nascimento
J
J
Neyts
D000577:Amides / Q000494:pharmacology*; D000818:Animals; D002460:Cell Line; D051379:Mice; D029322:Norovirus / Q000187:drug effects*; D011719:Pyrazines / Q000494:pharmacology*; D012367:RNA, Viral / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects*
D000577:Amides; D011719:Pyrazines; D012367:RNA, Viral; C462182:favipiravir